New Progress Made in China’s Treatment of COVID-19

Updated: Dec 18, 2020 04-15-2020

The Troika composed by Carrimycin, Chloroquine phosphate, and Favipiravir are expected to be promoted globally

At the press conference of the Joint Prevention and Control Mechanism of the State Council held at 15:00 on April 14th, relevant officials from the Ministry of Science and Technology of the PRC, the National Administration of Traditional Chinese Medicine, and the National Medical Products Administration answered questions raised by medias about progress in R&D on drugs and vaccines against COVID-19, etc.

When interviewed, the spokesperson at the conference pointed out that during this epidemic, a basic pattern of the main drugs had been formed at the moment through scientific research with “curable” as the main goal; a series of progress had been achieved in the development of new clinical treatment technologies, and the scientific research team was still actively promoting the deployment and research process of a new round of projects. In the future, the advancement of clinical research on drugs such as Carrimycin will be accelerated, aiming to realize more achievements faster for epidemic prevention and control.

Named twice, the clinical trials of Carrimycin, “drive into the fast lane”

Carrimycin was mentioned by name twice at this press conference. It is understood that Carrimycin is the world’s first class 1 new drug developed by using synthetic biology technology with independent Chinese intellectual property. The currently known clinical trial information shows that Carrimycin can remove the Corona Virus from the human body promptly and effectively, improve clinical symptoms and lung inflammation significantly, and is extremely safe compared to other drugs. Especially for severe and critically ill patients, virus recovery and patients with failed antiviral therapy, it has obvious effect without obvious adverse reactions.

The relevant person in charge of the Shenyang Tonglian Group pointed out in an interview that at present, the clinical trial of Carrimycin for the treatment of COVID-19 had entered the final stage. That “Accelerating the advancement of clinical research on Carrimycin” at this press conference will drive the devel